TRUGOLF RELEASES GROUNDBREAKING E6 APEX RANGE TRAINING SOFTWARE AND SIGNS JOE HALLETT, PGA COACH OF THE YEAR
April 08, 2024 09:00 ET
|
TruGolf Holdings, Inc.
SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc.(Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, today...
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024 18:49 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024 06:10 ET
|
Apogee Therapeutics, LLC
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to...
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 07, 2023 07:30 ET
|
Apogee Therapeutics, LLC
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every two- or three-month dosing Initial subcutaneous...
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
August 02, 2023 07:30 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 18, 2023 16:01 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
July 13, 2023 18:32 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic...
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Apogee Enterprises, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
January 02, 2019 12:53 ET
|
Schall Law
LOS ANGELES, Jan. 02, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Apogee Enterprises, Inc....
EARLY JANUARY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Apogee Enterprises, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 24, 2018 12:30 ET
|
Schall Law
LOS ANGELES, Dec. 24, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Apogee Enterprises, Inc....
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Apogee Enterprises, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 17, 2018 16:15 ET
|
Schall Law
LOS ANGELES, Dec. 17, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Apogee Enterprises, Inc....